Before Invest
GILEAD SCIENCES, INC. logo

GILEAD SCIENCES, INC.

GILD
Biological Products No Disgnostic Substances
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Statement
Income StatementBalance Sheet
Period
Annual Quarterly
Order
Unlock 14 years
Format
% Change
Rows
USD ($)
$ in Millions 		Dec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016Dec 31, 2015Dec 31, 2014Dec 31, 2013Dec 31, 2012Dec 31, 2011Dec 31, 2010Dec 31, 2009
Current assets:
                 
Cash and cash equivalents
$ 7,564
$ 9,991
$ 6,085
Assets
                 
Short-term marketable debt securities
68
0
1,179
Accounts receivable, net
4,913
4,420
4,660
Inventories
1,774
1,710
1,787
Deferred tax assets
1,964
-
-
Prepaid and other current assets
4,024
3,052
2,374
Prepaid taxes
-
-
-
Prepaid expenses
-
-
-
Other current assets
-
-
-
Total current assets
18,342
19,173
16,085
Noncurrent Assets
                 
Property, plant and equipment, net
5,606
5,414
5,317
Long-term portion of prepaid royalties
-
-
-
Long-term deferred tax assets
-
-
-
Long-term marketable debt securities
2,974
0
1,163
Intangible assets, net
16,978
19,948
26,454
Goodwill
8,314
8,314
8,314
Intangible assets
-
-
-
Other long-term assets
4,845
6,146
4,792
Total assets
59,023
58,995
62,125
Liabilities and Stockholders’ Equity
                 
Current liabilities:
                 
Accounts payable
715
833
550
Accrued rebates
4,337
3,892
3,802
Accrued and other current liabilities
-
-
-
Accrued compensation and employee benefits
-
-
-
Income taxes payable
-
-
-
Other accrued liabilities
-
-
-
Deferred revenues
-
-
-
Current portion of long-term debt, net
2,807
1,815
1,798
Other current liabilities
3,953
5,464
5,130
Total current liabilities
11,813
12,004
11,280
Noncurrent Liabilities
                 
Long-term deferred revenues
-
-
-
Long-term debt, net
22,129
24,896
23,189
Long-term income taxes payable
896
830
2,039
Deferred tax liabilities
402
724
1,588
Convertible senior notes, net
-
-
-
Other long-term liabilities
1,165
1,295
1,280
Temporary Equity
                 
Equity component of currently redeemable convertible notes
-
-
-
Stockholders’ equity:
                 
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding
0
0
0
Common stock, par value $0.001 per share; 5,600 authorized; 1,241 and 1,246 shares issued and outstanding, respectively
1
1
1
Additional paid-in capital
8,932
7,700
6,500
Accumulated other comprehensive income
39
132
28
Retained earnings
13,730
11,497
16,304
Total Gilead stockholders’ equity
22,703
19,330
22,833
Noncontrolling interest
(84)
(84)
(84)
Total stockholders’ equity
22,618
19,246
22,749
Total liabilities and stockholders’ equity
$ 59,023
$ 58,995
$ 62,125